FDA to end alternative summary reporting

The FDA is putting an end to a program that allowed medical device companies to keep the public in the dark about reports of harm and malfunction. The program, called alternative summary reporting, was established in 1997 and its data has not been publicly available.

The agency plans to make past data received through summary reporting publicly available in the coming weeks. The announcement comes a month after a Kaiser Health News investigation uncovered the program collected 1.1 million reports since 2016.

The change also comes as the medical device industry has recently come under fire after a Netflix documentary that debuted in mid-2018 slammed Bayer for its controversial birth control implant, Essure, which has been tied to thousands of injuries.

In particular, makers of breast implants have been able to report adverse events and keep the malfunctions and injuries opaque.

“We believe these steps for more transparent medical device reports will contribute to greater public awareness of breast implant adverse events,” FDA Principal Deputy Commissioner Amy Abernethy, MD, PhD, and Jeff Shuren, DM, JD, director of the FDA’s Center for Devices and Radiological Health, said in a statement.

However, the FDA noted the reports it receives can’t be used to determine the frequency of adverse events and that the reports are from an outside party.

The agency began ending its summary alternative reporting program in mid-2017, according to Kaiser Health News, but still accepted hundreds of thousands of injury reports

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”